drug delivery

Pharma

Recurv raises $24M to take nano-emulsion taxane to clinical POC

Recurv has created a candidate, RP-001, designed to focus taxane delivery on the tumor and thereby reduce its impact on healthy tissues. 
Nick Paul Taylor Feb 3, 2023 7:30am

Investors kibosh Midatech merger, triggering scramble for cash

Jan 24, 2023 10:08am

Loading mRNA into extracellular vesicles limits wrinkles in mice

Jan 17, 2023 10:15am

Biogen bets $10M on implant to improve delivery of Spinraza

Jan 10, 2023 7:25am

Mayo, InSitu pen prolonged-release cancer co-development pact

Jan 3, 2023 7:15am

Midatech plots pivot beyond delivery tech with Bioasis buyout

Dec 20, 2022 7:40am